Autism as a disorder of biological and behavioral rhythms: toward new therapeutic perspectives.
Sylvie Tordjman, Katherine S Davlantis, Nicolas Georgieff, Marie-Maude Geoffray, Mario Speranza, George M Anderson, Jean Xavier, Michel Botbol, Cécile Oriol, Eric Bellissant, et al.

To cite this version:
Sylvie Tordjman, Katherine S Davlantis, Nicolas Georgieff, Marie-Maude Geoffray, Mario Speranza, et al.. Autism as a disorder of biological and behavioral rhythms: toward new therapeutic perspectives.. Frontiers in Pediatrics, Frontiers, 2015, 3, pp.1. <10.3389/fped.2015.00001>. <hal-01134214>

HAL Id: hal-01134214
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01134214
Submitted on 23 Mar 2015

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Autism as a disorder of biological and behavioral rhythms: toward new therapeutic perspectives

Sylvie Tordjman1,2 *, Katherine S. Davlantis3, Nicolas Georgieff4, Marie-Maude Geoffray4, Mario Speranza5, George M. Anderson6, Jean Xavier7, Michel Botbol1,8, Cécile Oriol2, Eric Bellissant8,9, Julie Vernay-Leconte10, Claire Fougerou9,10, Anne Hespel1,10, Aude Tavenard9,10, David Cohen7, Solenn Kermarrec1, Nathalie Coulon7, Olivier Bonnot1 and Geraldine Dawson3

1 Laboratoire Psychologie de la Perception, Université Paris Descartes, CNRS, UMR 8158, Paris, France
2 Pôle Hospitalo-Universitaire de Psychiatrie de l’Enfant et de l’Adolescent (PHYUEA), Centre Hospitalier Guillaume Régnier, Université de Rennes 1, Rennes, France
3 Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA
4 Department of Child and Adolescent Psychiatry, Centre Hospitalier Le Vinatier, Lyon, France
5 Department of Child and Adolescent Psychiatry, Centre Hospitalier de Versailles, Université de Versailles Saint-Quentin-en-Yvelines, Le Chesnay, France
6 Child Study Center, Yale University School of Medicine, New Haven, CT, USA
7 Department of Child and Adolescent Psychiatry, Assistance Publique – Hôpitaux de Paris, Groupe Hospitalier Pitie-Salpetrière, CNRS FRE 2987, University Pierre and Marie Curie, Paris, France
8 Service Hospitalo-Universitaire de Psychiatrie de l’Enfant et de l’Adolescent, CHU de Brest, Université de Bretagne Occidentale, Brest, France
9 Clinical Investigation Center, INSERM CIC 0203, University Hospital, Rennes 1 University, Rennes, France
10 Department of Clinical Pharmacology, University Hospital, Rennes 1 University, Rennes, France
11 Pôle Hospitalo-Universitaire de Psychiatrie Adulte (PHUPEA), Centre Hospitalier Guillaume Régnier, Université de Rennes 1, Rennes, France

Edited by: Roberto Canitano, University Hospital of Siena, Italy
Reviewed by: Rajeshkhar Bipeta, Gandhi Medical College and Hospital, India
Felipe Ortuño, Clínica Universidad de Navarra, Spain
Roberto Canitano, University Hospital of Siena, Italy

*Correspondence: Sylvie Tordjman, Hospitalo-Universitaire de Psychiatrie de l’Enfant et de l’Adolescent, 154 rue de Chartillon, Rennes 35200, France
e-mail: s.tordjman@yahoo.fr

There is a growing interest in the role of biological and behavioral rhythms in typical and atypical development. Recent studies in cognitive and developmental psychology have highlighted the importance of rhythmicity and synchrony of motor, emotional, and interpersonal rhythms in early development of social communication. The synchronization of rhythms allows tuning and adaptation to the external environment. The role of melatonin in the ontogenetic establishment of circadian rhythms and the synchronization of the circadian clocks network suggests that this hormone might be also involved in the synchrony of motor, emotional, and interpersonal rhythms. Autism provides a challenging model of physiological and behavioral rhythm disturbances and their possible effects on the development of social communication impairments and repetitive behaviors and interests. This article situates autism as a disorder of biological and behavioral rhythms and reviews the recent literature on the role of rhythmicity and synchrony of rhythms in child development. Finally, the hypothesis is developed that an integrated approach focusing on biological, motor, emotional, and interpersonal rhythms may open interesting therapeutic perspectives for children with autism. More specifically, promising avenues are discussed for potential therapeutic benefits in autism spectrum disorder of melatonin combined with developmental behavioral interventions that emphasize synchrony, such as the Early Start Denver Model.

Keywords: autism spectrum disorder, biological rhythms, motor, emotional and relational rhythms, synchronization of rhythms, melatonin, Early Start Denver Model, therapeutics

INTRODUCTION

Endogenous physiological variations involved in biological rhythms reflect adaptation to the environment. Thus, the sleep–wake rhythm associated with biological circadian rhythms can be viewed as an adaptation to the day–night cycle. Circadian rhythms allow temporal organization of biological functions in relation to environmental changes (1). The periodicity of activities applies to all biological, physiological, and psychological functions; recently, the science of biological rhythms, chronobiology, has emerged with its own theory, science, and education (2).

Furthermore, recent studies in the field of cognitive and developmental psychology have highlighted the importance of rhythmicity and synchrony of motor, emotional, and relational rhythms in early development of social communication. Given the major role of the sleep hormone melatonin in the ontogenetic establishment of diurnal rhythms, the synchronization of peripheral oscillators (also termed clocks) and the regulation of human circadian rhythms (1), melatonin might be involved in the synchrony of motor, emotional, and relational rhythms.

Indeed, relationships might exist, based on the hypothesis of ergodicity (3), between cellular communication networks involving a cellular synchrony (synchronization of cellular oscillations by melatonin) and early social communication development involving a synchrony of motor, emotional, and interpersonal rhythms. Autism spectrum disorder (ASD) – a developmental disorder characterized by social communication impairments associated with repetitive interests and behaviors – provides an interesting and challenging model of abnormal melatonin production in early developmental disorders and its possible relationship with autistic behavioral impairments.
This article proposes a central role of rhythmicity and synchrony of rhythms in typical child development and offers a new integrative approach, which considers autism as a disorder of biological and behavioral rhythms. In this perspective, promising avenues will be discussed in this article for potential therapeutic benefits in ASD of melatonin and developmental behavioral interventions that emphasize rhythms and synchronization, such as the Early Start Denver Model (ESDM).

**PHYSIOLOGICAL AND BEHAVIORAL RHYTHM DISTURBANCES IN AUTISM**

**AUTISM AS A DISORDER OF BIOLOGICAL RHYTHMS**

Alterations in circadian sleep–wake rhythm have frequently been reported in autism (4, 5). More specifically, reduced total sleep and longer sleep latency as well as nocturnal and early morning awakenings are often observed in individuals with ASD (6–12). Furthermore, prior studies on melatonin in autism have all reported abnormalities in melatonin secretion (see Table 1). In addition, abnormalities in cortisol circadian rhythm have also been reported in autism (for a review, see Tordjman et al. (13)). In particular, significantly higher frequency of absence of circadian variation in melatonin and cortisol levels was observed in individuals with autism compared to typically developing controls. Golombek et al. (14) described the effects of circadian desynchrony that can enhance susceptibility to certain disorders (metabolic, immune, cognitive, and somatic disorders including cancer). It is noteworthy that congenitally blind children with consequently abnormal melatonin secretion and synchronization [the production of pineal-derived melatonin depends on the light acting through the retinohypothalamic tract (15)] very frequently display autism [up to 42% (16)], whereas hearing impaired children, including hearing loss, show autism less frequently [up to 10% (17)]. More specifically, abnormally low daytime and nighttime melatonin secretion was associated with an absence of melatonin circadian variation in some individuals with autism (18, 19), which in turn, given the role of synchronizer of melatonin, also has consequences on the circadian rhythms network, including the cortisol circadian rhythm (13, 20).

This blunted circadian rhythmicity with no or little variability might be related to the difficulties in adapting to changes typically observed in individuals with autism. Thus, children with autism who are confronted with physiological continuity due to absent circadian rhythms may have difficulties adapting to changes in either their external or their internal environment (26). Indeed, as previously underlined, the circadian clocks network, synchronized by melatonin and involving an internal system of continuity/discontinuity, allows adaptation to environmental changes.

Similarly, blunted circadian rhythmicity may explain the difficulty observed in many children with autism in adapting to variability.

<table>
<thead>
<tr>
<th>Study</th>
<th>Sample</th>
<th>Study group</th>
<th>Measured variable</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ritvo et al. (21)</td>
<td>Urine</td>
<td>Young adults with autism (N = 10)</td>
<td>Melatonin concentration</td>
<td>Increased daytime values compared to typically developing controls</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Similar nighttime values compared to typically developing controls</td>
</tr>
<tr>
<td>Nir et al. (22)</td>
<td>Serum</td>
<td>Young men with autism (N = 10)</td>
<td>Melatonin concentration</td>
<td>Increased daytime values compared to typically developing controls</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Decreased nighttime values compared to typically developing controls</td>
</tr>
<tr>
<td>Kulman et al. (19)</td>
<td>Serum</td>
<td>Children with autism (N = 14)</td>
<td>Melatonin concentration (24-h circadian rhythm)</td>
<td>Decreased nighttime values compared to typically developing controls</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No circadian variation in 10/14 (71.4%) children with autism</td>
</tr>
<tr>
<td>Tordjman et al. (23)</td>
<td>Urine</td>
<td>Children and adolescents with autism (N = 49)</td>
<td>6-Sulphatoxymelatonin excretion rate (12-h collection)</td>
<td>Decreased nighttime values compared to typically developing controls</td>
</tr>
<tr>
<td>Melke et al. (24)</td>
<td>Plasma</td>
<td>Adolescents and young adults with autism (N = 43)</td>
<td>Melatonin concentration</td>
<td>Decreased daytime values compared to typically developing controls</td>
</tr>
<tr>
<td>Mulder et al. (25)</td>
<td>Urine</td>
<td>Children and adolescents with autism (N = 20)</td>
<td>6-Sulphatoxymelatonin excretion rate (24-h collection)</td>
<td>Trend to lower 24-h melatonin excretion rate in hyperserotonemic compared to normoserotonemic individuals with autism</td>
</tr>
<tr>
<td>Tordjman et al. (18)</td>
<td>Urine</td>
<td>Post-pubertal adolescents and young adults with autism (N = 43)</td>
<td>6-Sulphatoxymelatonin excretion rate (split 24-h collection)</td>
<td>Decreased daytime values compared to typically developing controls</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Decreased nighttime values compared to typically developing controls</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No circadian variation in 10/43 (23.2%) individuals with autism</td>
</tr>
</tbody>
</table>
changes in rhythms of their external and internal environment. Thus, rapid rhythms of sensory stimuli in their external environment (e.g., repeated visual stimuli provided by a strobeoscopic light) can provoke epileptic seizures in some individuals with autism [approximately one-third of individuals with autism have epilepsy (27)]. Interestingly, EEG changes tended to be correlated with an abnormal rhythm of melatonin in young adults with autism (22). Furthermore, some parents have reported that their daughters with autism experience epileptic seizures toward the 14th day of their menstrual cycle, which is when luteinizing hormone (LH) levels peak (Tordjman, personal communication), suggesting that individuals with autism may have difficulties adapting to periodic hormonal changes in their internal environment. We can state the following hypothesis: a change in rhythm associated with excessive environmental stimuli might strongly increase arousal and lead to physiological stress which, for some individuals with autism, can disturb the rhythmic activity of a particular brain area, leading it to fall out of sync with the rest of the brain and causing its population of neurons to fire (depolarization and occurrence of an epileptic seizure). This underlines the importance of stable physiological rhythms.

Finally, significant relationships have been found between lower nocturnal melatonin excretion and increased severity of autistic social communication impairments, especially for verbal communication and social imitative play (18, 23). These findings are in agreement with studies suggesting an association between reduced melatonin production and language impairment (22, 28). Along the same line, the systemic administration in the animal model of Zebra Finch of a melatonin-1B receptor antagonist at the beginning of the night shortens the song and motif length and affects the song syllable lengths produced the next day (29). Reduced melatonin activity might create timing problems in biological clocks with physiological and psychological effects that might be, according to Boucher’s model of autism (30) and Wimpory’s theory (31), involved in autistic impairments, notably in autistic social communication impairments. It is noteworthy that deficiency in oxytocin (oxytocin is considered a bonding hormone (32, 33)) has also been reported in autism (34, 35) and bonding is involved in the development of very early social interaction in infants. Interestingly, the release of oxytocin by the posterior pituitary gland follows a robust circadian rhythm in mammals. Further studies are needed to better understand the underlying mechanisms of oxytocin anomalies in autism and to explore, in particular, possible oxytocin rhythm disturbances in ASD. The importance of the synchrony of rhythms in the development of social interaction and communication is detailed in the next section.

IMPORTANT OF SYNCHRONY OF RHYTHMS FOR SOCIAL COMMUNICATION IN TYPICAL DEVELOPMENT AND AUTISM SPECTRUM DISORDER

Several studies, based on animal models and human perinatal development, suggest that stable patterns of repeated stimuli in the form of maternal physiological rhythms, involving cross-modal perception such as regular cardiac rhythm, which provides the fetus with auditory and vibratory stimuli, allow the fetus to integrate sensory information facilitating prenatal perceptual learning and develop a coherent representation of his or her internal and external environment (36–38). Fluctuations in the physiological rhythms (variants), such as variations in the maternal cardiac rhythm and also variations in hormone levels involved in the circadian rhythms that are already present during the fetus life (the fetus’ circadian rhythms are the mother’s ones), occurring in a background of regular repetition of identical sequences (invariants), may help the fetus to develop the ability to adapt to change in an environment characterized by high regularity. As previously emphasized (38), very early mother–infant relations provide a secure environment based on the repetition of invariants, while at the same time promoting adaptation to change through the presence of variants. It is through the regular repetition of identical sequences of discontinuity, such as circadian rhythms, that a continuum is constructed associated with the development of adaptation to changes.

The development of the very earliest form of communication relies on the sharing of emotions between mother and infant, when, for example, the infant is suckling in his or her mother’s arms, through emotional synchrony that enhances the integration of sensory inputs (39, 40). Concerning memory processes, emotions enable to “fix” events, just as a photographic fixing agent sets images (38). Cortisol (a stress and arousal neurohormone) crosses the placental barrier. The cortisol circadian rhythm, as well as the melatonin circadian rhythm in the fetus and infant after birth, are those of maternal cortisol and melatonin. Indeed, the infant’s circadian cortisol and melatonin rhythms are only established between 2 and 3 months of age in typical development, at the same time that infants begin to have more regular sleep–wake cycles associated with nighttime sleep lasting 6–8 h (41, 42). Interestingly, this period coincides in typical development with the emergence of social smiling by the second month of life (43), the advent of mirror self-recognition at around 3 months of age (44), and increased brain activation to speech occurring between 3 and 4 months of age (45).

At birth, the human immaturity of the cerebral cortex allows initial learning to influence the neural architecture through perceptual-action mapping (46, 47). The infant’s social skills, especially including imitation, shared attention, and empathic understanding, also contribute to the development of learning (46, 48). Social synchrony can be defined as the dynamic and reciprocal adaptation of the temporal structure of behaviors between interactive partners (49). In typically developing children, the quality of social interaction depends on an active dialog between the parent and the infant (50, 51). Numerous studies have been emphasizing the importance of parent–infant synchrony and the construction of shared timing in social communication development (52).

Also, biological markers were associated with relational synchrony. First, oxytocin administration to parent enhances infant physiological and behavioral readiness for social engagement and parallels an oxytocin increase in infants (32). Second, neural correlates were found using hyper-scanning recordings of EEG brain activity and measures of neural synchronization between distant brain regions of interacting individuals through a free imitation task (53). Dumas and colleagues’ study (53) was the first to record dual EEG activity in dyads of subjects during spontaneous non-verbal interaction. Eleven same-sex pairs were scanned. They found that interpersonal rhythmic oscillations were correlated
with the emergence of synchronization in the brain's alpha–mu band between the right centro-parietal regions (an area involved in social interaction) of both participants. Developmental psychologists now study interaction not only as the addition of two behaviors but also as a global phenomenon in which synchrony is considered as social per se. To describe the dialog between two partners engaged in behavioral and affective exchange, developmental psychologists more and more take into consideration rhythm and temporal course of both behavior and affect, regarded as key expressions of adaptation during interaction (49, 52).

Only a few studies have addressed the importance of infant–caregiver synchrony/reciprocity in the development of social communication involving infants who subsequently are diagnosed with autism. It appears appropriate in the field of autism to consider the combined domain of social communication, as the most recent version of the ADOS scale does, as well as the recently released DSM-5 American classification. Methods to investigate this issue include studies using early home videos (54), parental interviews focusing on early abnormalities (55), and prospective assessment of children at risk of ASD (e.g., siblings) (56, 57). Studies have revealed a pervasive developmental course in infants who were later diagnosed with ASD. Thus, the first signs were abnormalities in eye contact, imitation, disengagement, joint attention, orienting to name, and body language. These behaviors are parts of the affective tuning disturbances; the term affective tuning, defined by Stern (58) as the “execution of behaviors expressing the emotional ownership of a shared affective state,” refers to infant–caregiver emotional communication based on rhythm similarity from the second semester of life onward. Also, these behaviors are important precursors of later-developing symptoms. However, whether these first signs impair early infant–parent interactions and whether they reflect already autistic behavioral impairments in the infant remain to be explored. In two related studies based on home movies of children later diagnosed with autism, Saint-Georges et al. (54) and Cohen et al. (59) showed that motor and emotional asynchrony was present between infants and parents before 12 months of age, and parents perceived weaker initiatives from their children. In addition, parents experienced weaker interactive responsiveness from their children and increasingly tried to compensate this perceived deficit by soliciting behaviors through touching the infant. This was particularly observed after 12 months of age for the fathers of infants who were later diagnosed with autism.

Many authors have studied imitation in children with autism (imitation of other people's faces, gestures, or vocal signals) in order to better understand the development of autistic social communication impairments. This specific type of imitation is referred to as “spatial” imitation to highlight the capacity to produce an instantaneous copy of the form of the signal. However, another way to communicate with others is to perform a “temporal” imitation of their behavior (60). This is what humans do through rhythmic finger or foot tapping, dancing, singing, and drumming in synchrony with others (61). Xavier et al. (62) highlighted the importance of rhythmicity and synchrony in the development of children's imitative exchanges with peers. From birth, a child has a predisposition to engage, intersubjectively, with the rhythmic actions and awareness of other persons, and to move in synchrony with them (44, 63). Synchronic imitation is an important preverbal way to communicate among peers (64, 65). This reciprocal experience concerns two children able and motivated to coordinate their behavior with the non-ritualized behavior of the other, in both form and timing and to alternate turns between model and imitator (66). The impression of fluidity in the coordination of movements between partners is underlined by mutual attention, engagement, continuous adaptation, and turn taking (67). This rhythmic process made of ludic spontaneous imitation reveals moments of discontinuity occurring in a background of continuity. Neural bases of this coupling activity are constituted by the neuron mirrors system (68), with the same evidence showing that the neuronal structures involved when a mental state is experienced, are also recruited during the observation of others. Guionnet et al. (69) designed a free imitation paradigm in an fMRI study to examine some neural correlates of social interaction. Their results agree with those previously evidenced (70, 71) concerning the core circuit of imitation, but they found different activations between the situation of imitating and that of being imitated.

A special quality of temporal imitation is the ability to use different motor movements in order to communicate. Thus, simple finger tapping can be synchronized with another's head nodding or trunk movements, whether entrained by one of the movements or in response to external synchronizing stimuli such as music. Although animals and humans can perceive rhythms and produce rhythm motor patterns, only humans can adapt their rhythm movements to external rhythms (72) [with the exception of the cockatoo (73)]. The ability to be rhythmically synchronized with the environment appears important for infant development in the emotional, cognitive, social, and sensorimotor realms (44, 74). It has been demonstrated that the human fetus and newborn already have the capacity to perceive and produce rhythms (75). The ability to produce temporally adapted motor patterns comes later and depends on the specific motor system involved and the relationship between the beat presented and the spontaneously occurring motor tempo of the infant (76, 77). It should be fruitful to longitudinally examine children with autism in terms of ability to adapt their own rhythm to external rhythms. Interestingly, clinical observations suggest that some children with autism are able to respond to an external rhythmic vocalization by a similar rhythm motor pattern such as hand flapping (Tordjman, personal communication). However, previous studies reported disorganized rhythms, stereotypies, and poor synchrony in most of these children (78), which might be related to the low melatonin levels reported to be associated in autism with the severity of verbal communication and social imitative play impairments (18, 23). Melatonin, as a regulator of physiological rhythms and oscillations, might enhance the capacity of children with ASD to synchronize their movements with movements of others (this synchronization of movements is needed for imitative play) and with external rhythmic auditory stimuli (such as music and/or human voice enhancing their verbal skills). Interestingly, in a study of social smiling in infants (79), there was no difference in frequency of smiling between 2- and 5-month-old infants with and without ASD during infant–caregiver face-to-face interactions. However, whereas typically developing infants showed a significant increase
in smiling rate when caregivers were smiling, smiling in infants later diagnosed with ASD was not synchronized with smiling in caregivers and was not contingent upon caregiver behavior (caregiver facial expressions and vocalizations). Furthermore, it is noteworthy that, as previously indicated in this section, the infant’s melatonin circadian rhythm is established between 2 and 3 months of age, and a study (80) reported that eye contact was normal in 2-month-old infants later diagnosed with autism but declined between 2 and 6 months of age, suggesting an additional argument in favor of a possible relationship between the well-replicated nocturnal melatonin deficit in autism (see Table 1) and the development of autistic social communication impairments.

### REPETITIVE BEHAVIORS AND INTERESTS

Repetitive behaviors and interests are defined, according to DSM-5 criteria (81), as a repetition of identical sequences of behaviors for motor stereotypes (motor stereotypes involve repetitive mal-adaptive movements) or thoughts for restrictive patterns of interests (restrictive and repetitive interests involve fixated interests, adherence to routines, or ritualized and rigid thinking patterns). Thus, repetitive behaviors and interests can be viewed as behavioral responses to the need to create discontinuity that is repeated at regular intervals, which could have been fundamentally lacking in the physiological development of children with autism due to the melatonin deficit reported in autism. Our finding (18) observed in a sample of 43 adolescents and young adults with autism (nicturnal excretion of 6-SM was significantly negatively correlated with repetitive use of objects), taken together with improvement of stereotyped behaviors following administration of melatonin in 24 children and adolescents with ASD (82), supports this hypothesis.

The autistic deficit in melatonin secretion might lead to physiological rhythm disturbances in autism impairing biological circadian rhythms and even, in certain cases, to an “endless” physiological continuity provoked by the absence of variation in melatonin levels. From this perspective, stereotyped behaviors and interests can be seen as offering to children with autism rhythmic forms providing rhythmic continuity and discontinuity through the creation of repeated identical patterns. Albert Goldbeter (83), director of the Chronobiology Unit at the Brussels Sciences University, underlines findings might be specific to autism or whether melatonin’s effect might vary considerably with age and pubertal status (23). Studies have also been limited by small sample sizes (90–93, 95, 96, 98, 102, 104). In larger studies, heterogeneous groups are often examined and have included blind individuals and individuals with various neurological disabilities with concomitant intellectual disability. In such studies, often results seen for the autism subgroup are not separately presented (97, 100, 103–107). The specificity and interpretation of the results with respect to autism are often unclear. Additional research is needed to determine whether and which findings might be specific to autism or whether melatonin’s effect might be similar across groups. It can be hypothesized that melatonin’s effects are due to actions on certain behavioral dimensions and that they can be observed across disorders. However, it should be pointed out that in our studies (18, 23), lower melatonin excretion was significantly associated with social communication impairments rather than with sleep problems. Future studies of melatonin in ASD should simultaneously examine melatonin levels, sleep problems, autistic behavioral impairments, and level of functioning so that a more complete picture can emerge.

It is worth noting that just a few of the therapeutic trials of melatonin have assessed effects on autistic behavioral impairments. These include reports of improved communication (105), reduced social withdrawal (82, 99), decreased stereotyped behaviors and rigidity (82, 102), and reduced anxiety (99, 103). Furthermore, at the time the improvements noted were not sufficiently detailed. For example, Wright et al. (105) reported significant...
<table>
<thead>
<tr>
<th>Study</th>
<th>Journal</th>
<th>Population</th>
<th>Design</th>
<th>Duration of treatment</th>
<th>Melatonin (formulation, dose)</th>
<th>Time of intake</th>
<th>Main outcome measures</th>
<th>Effects on sleep</th>
<th>Other outcomes</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SINGLE CASE REPORTS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Horrigan and Barnhill [90]</td>
<td>J Am Acad Child Adolesc Psychiatry</td>
<td>17-year-old boy with Asperger’s Syndrome (AS)</td>
<td>–</td>
<td>Not given</td>
<td>3 mg</td>
<td>20–30 min before bedtime (BB)</td>
<td>Sleep</td>
<td>Sleep improvement. No side effects</td>
<td>Daytime behavior improvement</td>
<td>–</td>
</tr>
<tr>
<td>Hayashi [91]</td>
<td>Psychiatry Clin Neurosci</td>
<td>14-year-old boy with autistic disorder, severe intellectual disability and phase delay with polyphasic sleep</td>
<td>–</td>
<td>4 months</td>
<td>Immediate release (IR) 6 mg</td>
<td>11:00 p.m.</td>
<td>Sleep</td>
<td>Melatonin increased sleep duration. No side effects</td>
<td>None</td>
<td>–</td>
</tr>
<tr>
<td>Jan et al. [92]</td>
<td>Dev Med Child Neurol</td>
<td>12-year-old boy with AS and complex sleep disturbance (phase delay and parasomnias)</td>
<td>–</td>
<td>6 months</td>
<td>Controlled release (CR) 5 mg</td>
<td>30 min BB</td>
<td>Sleep</td>
<td>Normalization of the sleep-wake rhythm and disappearance of parasomnias. No side effects</td>
<td>None</td>
<td>–</td>
</tr>
<tr>
<td><strong>RETROSPECTIVE STUDIES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gupta and Hutchins [33]</td>
<td>Arch Dis Child</td>
<td>9 cases of children with autistic disorder (AD) aged from 2 to 11 years. Chronic sleep problems</td>
<td>Not given</td>
<td>1 week to 1 year</td>
<td>IR 2.5–5 mg</td>
<td>45 min BB</td>
<td>Parental evaluation of sleep</td>
<td>56% showed improvement in total sleep duration</td>
<td>None</td>
<td>No standardized collection of sleep variables</td>
</tr>
<tr>
<td>Andersen et al. [94]</td>
<td>J Child Neurol</td>
<td>107 children and adolescents aged from 2 to 18 years with ASD (DSM-IV): 71% AD, 5% AS, 19% PDDNOS (pervasive developmental disorder not otherwise specified)</td>
<td>Not given</td>
<td>Mean duration: 1.8 years</td>
<td>IR in 81% of the cases. Dose escalation protocol from 1 to 6 mg based upon age</td>
<td>30–60 min BB</td>
<td>Parental evaluation of sleep</td>
<td>Parents reported full (25%) or partial (60%) improvement. Beneficial effects of melatonin seem to stop after 3–12 months despite the use of higher doses. Side effects observed in 3 children: sleepiness, fogginess, increased enuresis</td>
<td>None</td>
<td>No standardized collection of sleep variables. The loss of response to melatonin treatment is discussed in the text</td>
</tr>
<tr>
<td>Galli-Carminatti et al. [95]</td>
<td>Swiss Med Wkly</td>
<td>8 adult patients with AD (ICD-10) and intellectual disability, aged from 19 to 52 years</td>
<td>Not given</td>
<td>6 months</td>
<td>IR. Dose escalation protocol from 3 to 9 mg if clinically required</td>
<td>45 min BB</td>
<td>Sleep ( CGI-S and CGI-I)</td>
<td>Improvement in sleep onset latency, night and early morning awakenings. No side effects</td>
<td>None</td>
<td>No standardized collection of sleep variables. Two to four associated psychotropic drugs per patient</td>
</tr>
<tr>
<td><strong>OPEN-LABEL TRIALS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan et al. [96]</td>
<td>Dev Med Child Neurol</td>
<td>15 children with multiple neurological disabilities and severe sleep disorders</td>
<td>Not given</td>
<td>Not given</td>
<td>2–10 mg</td>
<td>Bedtime</td>
<td>Not given</td>
<td>Partial improvement in sleep disorders. No side effects</td>
<td>Behavior and social improvement</td>
<td>Heterogeneous sleep disorders and neurological disabilities</td>
</tr>
<tr>
<td>Ishizaki et al. [97]</td>
<td>No To Hattatsu</td>
<td>50 children and young adults with autism (n = 27) or mental retardation (n = 20) or severe motor/intellectual disability (n = 3) aged from 3 to 28 years with sleep disorders</td>
<td>Not given</td>
<td>Not given</td>
<td>Not given</td>
<td>Not given</td>
<td>Sleep disorders and emotional/behavior disturbances</td>
<td>34 patients experienced improvement in response to melatonin. Side effects reported in 17 patients</td>
<td>Improvements in excitability when sleep also improved. No change in contentious, stereotyped behavior and in school/workshop refusal</td>
<td>Various types of insomnia and diagnoses</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Study</th>
<th>Journal</th>
<th>Population</th>
<th>Design</th>
<th>Duration of treatment</th>
<th>Melatonin (formulation, dose)</th>
<th>Time of intake</th>
<th>Main outcome measures</th>
<th>Effects on sleep</th>
<th>Other outcomes</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paavonen et al. (98)</td>
<td>J Child Adolesc Psychiatry</td>
<td>15 children with AS (DSM-IV) aged from 6 to 17 years with severe sleep problems for at least 3 months</td>
<td>Not given</td>
<td>14 days</td>
<td>IR 3 mg</td>
<td>30 min BB</td>
<td>Sleep (72 h-period actigraphy, sleep diaries), daytime behavior (Karinina Sleepiness Scale, KSS, Child Behavior Checklist (CBCL))</td>
<td>Melatonin treatment was associated with significant decrease in sleep onset latency and nocturnal activity. Discontinuation of melatonin led to a significant decrease in sleep duration and more nocturnal activity. Side effects in 20% of the cases: tiredness, headaches, severe sleepiness, dizziness, diarrhea</td>
<td>Significant improvement of daytime behavior (CBCL)</td>
<td>No principal outcome specified. KSS is not validated in children nor in ASD</td>
</tr>
<tr>
<td>Giannotti et al. (99)</td>
<td>J Autism Dev Disord</td>
<td>29 children with AD (DSM-IV) aged from 2 to 9 years with current sleep problems</td>
<td>Controlled-release melatonin</td>
<td>6 months</td>
<td>Dose escalation protocol from 3 mg (&gt;1 mg of IR = 2 mg of CR) to 6 mg when clinically required, based upon age (max 4 mg under 4 years old and max 6 mg over 6 years old)</td>
<td>08:00 p.m.</td>
<td>Sleep (diaries and Children's Sleep Habits Questionnaire (CSHQ), daytime behavior, Childhood Autism Rating Scale (CARS))</td>
<td>Melatonin treatment was associated with improvement in sleep onset latency, night awakenings, and sleep duration, which vanished after melatonin discontinuation. No side effects</td>
<td>Parents reported less irritability, less anxiety, and better mood. Significant improvement of depression, anxiety, and withdrawal symptoms during melatonin treatment in children with AD. No effect was reported on the CARS</td>
<td>No principal outcome specified. Missing data: analyses on 25 patients</td>
</tr>
<tr>
<td>De Leersnyder et al. (100)</td>
<td>Pediatr Neurol</td>
<td>88 children with heterogeneous neurodevelopmental disorders (Smith-Magenis syndrome, mental retardation, encephalopathy, Angelman syndrome, Rett syndrome, Bourneville syndrome, blindness, and autism) aged from 5 to 26 years. Seven patients with autism, mean age 12 years old</td>
<td>6 years of open-label follow up</td>
<td>3 months</td>
<td>CR 2-4 mg (&lt;40 kg) or 6 mg (&gt;40 kg) based upon weight</td>
<td>60 min BB</td>
<td>Parental evaluation of sleep and mood self-constructed questionnaire</td>
<td>According to parental reports, both sleep latency and sleep duration improved within 3 months such as night awakenings, sleep quality, and daytime napping. Eleven children experienced adverse events (daytime nap, difficulties in swallowing tablets) that the parents attributed to melatonin treatment</td>
<td>12% of the parents reported improvements of mood in their children</td>
<td>Heterogeneous neurodevelopmental disorders. Results cannot apply to a population with autism spectrum disorders. No standardized collection of sleep and mood parameters. Mean dose for patients with autism: 5.7 mg</td>
</tr>
<tr>
<td>Malow et al. (82)</td>
<td>J Autism Dev Disord</td>
<td>24 children with ASD (DSM-IV-ADOS): AD, AS, and PDDNOS aged from 3 to 18 years. Sleep onset delay of 30 min or longer confirmed on actigraphy. Exclusion of neurodevelopmental disabilities such as fragile X, Down, and Rett syndromes</td>
<td>Before treatment families received structured sleep education and children underwent a treatment acclimation phase in order to be sure the melatonin will be taken</td>
<td>14 weeks</td>
<td>CR. Dose escalation protocol from 2 to 9 mg when clinically required</td>
<td>30 min BB</td>
<td>Sleep (actigraphy, Children’s Sleep Habits Questionnaire; CSHQ, diaries), daytime behavior (Child Behavior Checklist; CBCL, Repetitive Behavior Scale-Revised), parental stress (Parenting Stress Index Short Form), side effects (Hague Side Effects Scale)</td>
<td>Significant improvement in sleep latency within the first week of treatment but not for other sleep parameters such as night awakenings and sleep quality</td>
<td>Significant improvement in children’s behavior (withdrawal, affective problems, attention-deficit hyperactivity, stereotypy, and compulsive behaviors). Significant improvement in parental stress</td>
<td>No placebo</td>
</tr>
<tr>
<td>Study</td>
<td>Journal</td>
<td>Population</td>
<td>Design</td>
<td>Duration of treatment</td>
<td>Melatonin (formulation, dose)</td>
<td>Time of intake</td>
<td>Main outcome measures</td>
<td>Effects on sleep</td>
<td>Other outcomes</td>
<td>Comments</td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------------------</td>
<td>-----------------------------------------</td>
<td>------------------------------------------</td>
<td>-----------------------</td>
<td>------------------------------</td>
<td>----------------</td>
<td>-----------------------</td>
<td>----------------</td>
<td>---------------</td>
<td>----------</td>
</tr>
<tr>
<td>McArthur and Budden</td>
<td>Dev Med Child Neurol</td>
<td>9 children and adolescents with Rett syndrome aged from 4 to 17 years. Mean age: 10 years old</td>
<td>Randomized double-blind crossover trial</td>
<td>2 periods of 4 weeks with a wash out period of 1 week</td>
<td>2.5–7 mg based on weight</td>
<td>60 min BB</td>
<td>Sleep (actigraphy, diaries)</td>
<td>Significant improvement in total sleep time. No side effects</td>
<td>None</td>
<td>–</td>
</tr>
<tr>
<td>Gantand and Wallis</td>
<td>Health Dev Child Care</td>
<td>11 children and adolescents with ASD aged from 5 to 15 years. Mean age: 10 years old</td>
<td>Randomized double-blind crossover trial</td>
<td>2 periods of 4 weeks with a wash out period of 1 week</td>
<td>IR 5 mg</td>
<td>60 min BB</td>
<td>Sleep (diary)</td>
<td>Melatonin and placebo were associated with significantly decreased sleep latency and nocturnal awakenings, increased total sleep time. No side effects</td>
<td>Several parents and class teachers commented that their children were easier to manage and less rigid in their behavior while taking melatonin</td>
<td>ASD criteria were not consensual. Only 7 children completed the trial. Investigators found that some of the placebo capsules were empty. Missing data</td>
</tr>
<tr>
<td>Wasdell et al. (103)</td>
<td>J Pineal Res</td>
<td>51 children and adolescents with neurodevelopmental disabilities (16 patients with ASD) aged from 2 to 18 years. Sleep delay phase syndrome and impaired sleep maintenance with resistant to sleep hygiene intervention</td>
<td>Randomized double-blind crossover trial, Three weeks trial followed by a 3-month open-label study. Behavioral sleep treatment before inclusion</td>
<td>2 periods of 10 days with a wash out period of 3–6 days</td>
<td>Dose escalation protocol based on unspecified conditions: from 5 mg to 15 mg</td>
<td>20–30 min BB</td>
<td>Sleep (actigraphy, diaries, CGI-S, CGI-I, familial stress, family stress scale)</td>
<td>Significant improvement in total sleep duration and sleep latency as well as reduced stress levels in parents in the melatonin arm</td>
<td>Half of the patients with ASD had their dose increased during the open-label phase with no additional improvement in sleep latency or sleep duration, but caregivers reported less anxiety</td>
<td>Unspecified ASD criteria. Fifty patients completed the trial and 47 completed the open-label phase. Selection bias due to previous melatonin treatment (25% of the cases). At the end of the trial, 29 patients received a dose of 10 or 15 mg. Higher doses were necessary in patients with bilateral cerebral lesions</td>
</tr>
<tr>
<td>Wirojana et al. (104)</td>
<td>J Clin Sleep Med</td>
<td>12 children and adolescents with unspecified sleep problems, aged from 2 to 15 years. 5 patients with AD (ADOS and ADI-R), 3 patients with fragile X syndrome with AD, 3 patients with AD and fragile X syndrome, and 1 patient with fragile X premutation</td>
<td>Randomized double-blind crossover trial</td>
<td>2 periods of 2 weeks. No wash out period</td>
<td>IR 3 mg</td>
<td>30 min BB</td>
<td>Sleep (actigraphy, diary)</td>
<td>Significant, but mild improvement in total sleep time (+21 min) and decrease in sleep latency (−28 min)</td>
<td>None</td>
<td>Missing data: only 12 patients completed the trial (order bias). No subgroup analysis in AD patients. No side effects</td>
</tr>
<tr>
<td>Wright et al. (105)</td>
<td>Dev Disord J Autism</td>
<td>22 children and adolescents aged from 3 to 16 years with ASD (ICD-10, ADOS, ADI-R): AD (70%), AS (10%), and AA (20%). No fragile X or Rett syndrome. Current sleeplessness (confirmed on a 1-month diary) and resistant to behavioral treatment</td>
<td>Randomized double-blind crossover trial</td>
<td>2 periods of 3 months separated by 1 month of washout</td>
<td>IR1. Dose escalation protocol from 2 to 10 mg when clinically required</td>
<td>30–40 min BB</td>
<td>Sleep (sleep difficulties questionnaire, diary), daytime behavior (Developmental Behavior Checklist), side effect questionnaire</td>
<td>Significant improvement in sleep latency (−47 min) and total sleep duration (−52 min) in the melatonin arm. No improvement in night awakenings. The side effect profile was not significantly different between the 2 groups</td>
<td>Improvement in children's behavior in the melatonin arm that was significant for communication (p = 0.045)</td>
<td>Missing data. Analysis on 16 patients. No actigraphy. Mean melatonin dose: 7 mg</td>
</tr>
</tbody>
</table>
Table 2 | Continued

<table>
<thead>
<tr>
<th>Study</th>
<th>Journal</th>
<th>Population</th>
<th>Design</th>
<th>Duration of treatment</th>
<th>Melatonin (formulation, dose)</th>
<th>Time of intake</th>
<th>Main outcome measures</th>
<th>Effects on sleep</th>
<th>Other outcomes</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cortesi et al. (106)</td>
<td>J Sleep Res</td>
<td>160 children with ASD (DSM-IV-ADHD-ADD, ADD) aged from 4 to 10 years with sleep onset insomnia and impaired sleep maintenance</td>
<td>Randomized placebo-controlled, randomized in 4 groups: (1) melatonin alone (2) melatonin-augmented behavioral therapy (CBT) (3) CBT alone (4) placebo</td>
<td>12 weeks</td>
<td>CR 3 mg</td>
<td>09:00 p.m.</td>
<td>Sleep latency, Children's Sleep Habits Questionnaire, diaries</td>
<td>Melatonin increased total sleep time by 22.4 min (diaries) and 13.3 (actigraphy); reduced sleep onset latency by 37.5 min (diaries) and 45.3 (actigraphy). Children in the melatonin group woke up earlier than the children in the placebo group. Melatonin was most effective in children with longer sleep latency. Adverse events were similar between the 2 groups.</td>
<td>None</td>
<td>–</td>
</tr>
<tr>
<td>Gringas et al. (107)</td>
<td>BMJ</td>
<td>146 children aged from 3 to 15 years with neurodevelopmental disorders (160 patients with ASD and severe sleep disorders that did not respond to standardized sleep advice)</td>
<td>Double-blind randomized multicentre placebo-controlled phase III trial</td>
<td>12 weeks</td>
<td>Immediate release melatonin (dose escalation protocol from 0.5 to 12 mg) or matching placebo</td>
<td>45 min before bedtime</td>
<td>Total sleep time after 12 weeks (sleep diaries and actigraphy); sleep onset latency; child behavior (Aberrant Behavior Checklist); family functioning; adverse events</td>
<td>Melatonin increased total sleep time by 22.4 min (diaries) and 13.3 (actigraphy); reduced sleep onset latency by 37.5 min (diaries) and 45.3 (actigraphy). Children in the melatonin group woke up earlier than the children in the placebo group. Melatonin was most effective in children with longer sleep latency. Adverse events were similar between the 2 groups.</td>
<td>Child behavior and family functioning outcomes showed significant improvement and favored use of melatonin</td>
<td>The results are not specified by category of developmental disorder</td>
</tr>
</tbody>
</table>

DISORDER EARLY START DENVER MODEL IN AUTISM SPECTRUM SYNDROME

Although there is a growing interest in the role of motor, emotional, and relational rhythms in autism, there have been only a few attempts to focus on behavioral synchrony and its impact on education and development of children with autism. Many studies have attempted to provide a theoretical framework that is consistent with the identification and treatment of autism spectrum disorders. Dawson (119, 120), is a comprehensive developmental and educational intervention for children with autism. The ESDM, developed by Sally Rogers and Geraldine Dawson (119, 120), is a comprehensive developmental and educational intervention for children with autism. The ESDM, developed by Sally Rogers and Geraldine Dawson (119, 120), is a comprehensive developmental and educational intervention for children with autism.
Table 3 | Review, meta-analysis, and discussion of therapeutic uses of melatonin in autism

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan and O'Donnel (108)</td>
<td>Review based on 100 individuals with chronic sleep disorders, aged from 3 months to 21 years. Half of these 100 patients presented visual impairment or blindness. Melatonin dose ranged from 2.5 to 10 mg. Higher doses were needed in patients with impaired sleep maintenance. Partial or total improvement in sleep parameters was found in 82% of the cases. No side effects</td>
<td>Jan et al. (109)</td>
<td>Dev Med Child Neurol</td>
<td>Systematic review of studies on melatonin in children. Twenty-four studies found, most of them were case reports or uncontrolled studies with small samples. Mean age: 10 years old. Associated diagnosis: blindness and neurodevelopmental disabilities, 1 single case of an adolescent with AS (70). Doses ranged from 0.5 to 20 mg. Improvement in sleep in all the studies</td>
<td>Phillips and Appleton (110)</td>
<td>Dev Med Child Neurol</td>
<td>Only three studies, reporting a total of 35 children, fulfilled the criteria for inclusion (randomized controlled clinical trials). Two of them reported a significant decrease in time to sleep onset</td>
</tr>
</tbody>
</table>
The ESDM is both a curriculum and a set of teaching practices. A specific developmental curriculum, administered every 3 months in typical practice, defines the skills to be taught at any given time. In addition, a manual of teaching practices outlines the ways in which these skills are to be taught. Embedded within both the curriculum and the set of teaching practices is a focus on rhythms and synchrony. In other words, when therapists are working within the model, a focus on rhythms permeates both what they teach and how they teach it.

The ESDM curriculum outlines skills to be taught in multiple areas, including cognitive, social–emotional, and language domains. The curriculum focuses heavily upon the teaching of skills that promote engagement with other people in a synchronous, rhythmic way. Many young children with autism enter an ESDM program with weaknesses in these skills, such as imitation, joint attention, orienting to name, and eye contact, and these have broad influences upon the manner in which these children can engage with others. It is well recognized that learning occurs within a social context and that social skills, such as imitation and shared attention, provide a foundation for many aspects of learning, including language, cognitive, and social–emotional abilities. Thus, the ESDM focuses heavily on the development of social engagement and interactional synchrony early on in order to further support learning of a wide range of skills.

One area of focus within the ESDM, which is closely tied to the concept of rhythm, is imitation. Young children with autism often exhibit deficits in their imitation skills, including those of imitating others’ facial expressions and movements, gestures, body actions, and actions on objects. From the beginning of a young child’s ESDM program, teaching of imitation is stressed, from basic imitation of actions on objects to more nuanced imitation of sound effects produced in play. Spontaneous and appropriate imitation of others is typically rhythmic and marked by mutual attention, continuous adaptation, and turn taking. The beginning stages of facilitating imitation and social engagement often start with imitating the child, thereby entering into a rhythmic interaction with the child. By imitating the child’s movements and establishing a synchronous interaction, eye contact and mutual engagement in the interaction are promoted (125).

Rhythmicity is also involved in the way teaching occurs within the ESDM upon multiple levels, from the basic structure of each interactive routine to the ways in which adults engage with children during interaction. Social communication is about sharing moments of synchrony with others, and the ESDM supports the emergence of interactional synchrony. The therapist facilitates the occurrence of synchronous moments and strings them together into routines in which the therapist can naturally embed teaching opportunities. The primary vehicle through which all teaching is accomplished in this model is the joint activity routine, which is permeated by moments of rhythmic, synchronous interaction, and enriched with positive affect. Adult and child are attuned to one another, both taking the lead, both following the other’s lead, taking turns, and creating a positive and motivating activity in conjunction with one another.

The joint activity routine, although flexible and naturalistic, adheres to a four-part structure: (1) opening, (2) theme, (3) elaboration, and (4) closing. This structure provides a set of invariants, against which multiple variants can occur at differing levels. In order to begin engagement within a joint activity routine, the adult works hard to find the child’s smile. This can often be accomplished by getting into the child’s own rhythm (imitating a child’s actions), a very powerful tool to facilitate motivated response and interaction or by finding a rhythm that the child likes. For example, perhaps a child finds a toy drum and begins banging on it with his hand. In the ESDM, the therapist would join the child and would likely take her/his own drum and imitate the child’s actions, joining his rhythm. This would be considered the opening phase of the joint activity routine.

Next, the child and adult would develop a theme. This can be considered a continuation of the rhythm introduced during the
Tordjman et al. Melatonin and ESDM in autism

opening phase – in our example, banging a drum slowly with hands. The adult and child would take turns doing so, each leading and each following. The skillful adult would embed teaching opportunities into these turns – perhaps a focus on eye contact during dyadic engagement, or on imitation of actions on objects, or on giving and taking objects with eye contact. Both partners then play within this rhythm for a while, until one introduces a variant, or elaboration. In the ESDM, elaboration occurs by introducing a change into the joint activity routine, a change in the rhythm which often allows different teaching targets to be practiced. In this example, the child and adult might start to play peek-a-boo behind the drums. A new rhythm would need to be established, and both partners would work together in order to do so. An elaboration of this sort is a rhythmic fluctuation occurring against a background of invariants (e.g., the same interactive partner, the same material, the same setting), which allows the child to learn to adapt to change and teaches the child how to engage with people and materials differently. Finally, this rhythm would likely begin to fade, the teaching value of the activity would start to diminish, and/or the child would begin to lose motivation.

The fourth stage of the joint activity routine – the closing – is the last part of the joint activity routine. Adult and child might help one another clean up the materials, and then both partners would begin an entirely new joint activity routine. This could often involve a change in location, activity level, or teaching domain, and an entirely new set of coordinated interactions would be developed.

Within the joint activity routine, synchrony pervades within several different levels and in several different areas. Adult and child are attuned to one another and responsive to one another in terms of sensory input and output, motor actions, and emotions. Coordinated dyadic engagement, well-balanced in terms of leader and follower, pervades a high-quality joint activity routine. It is quite natural to view this ever-present synchrony in terms of a focus on shared nuanced rhythms.

There is also a focus on rhythmicity within some of the broader teaching practices of the ESDM; for example, in the way in which a teaching session is constructed. As mentioned above, teaching is delivered within joint activity routines. For a therapist-delivered session, these routines are strung together within a session to occupy a full 1- or 2-h time period. Within that time period, therapist and child move around to occupy several spaces. In a well-coordinated way, they engage together in a joint activity routine at the table, and then may move onto the floor for the next. They may sit together, then they may stand or walk or run. The child’s level of arousal is carefully monitored, and the session is marked by alternations of quiet thoughtfulness and active play, all coordinated artfully by a skilled adult. All of these changes occur against a stable background, as the session is marked by stability and continuity, with the introduction of variants when appropriate. The ESDM, a comprehensive, behavioral, and developmental early intervention designed for infants and toddlers with autism, is rooted within a sense of and appreciation for rhythmicty and synchrony at multiple levels, ranging from the specific skills that are taught to how those skills are taught, woven together and supported by a broader structure focused on maintaining a well-coordinated, synchronous set of dyadic interactions.

CONCLUSION: TOWARD AN INTEGRATIVE APPROACH COMBINING THE USE OF MELATONIN WITH THE ESDM

Taken all together, ASD could be seen as a disorder of rhythmicity with, more specifically, impairments in the synchrony of rhythms. Alternatively, such asynchrony might play an important role in a possibly large subgroup of individuals that forms part of the heterogeneous ASD category. In this article, we proposed an integrative approach to study desynchronization in biological and psychological rhythms in ASD and develop an etiopathogenic hypothesis as well as therapeutic perspectives for ASD based on this integrative approach. Indeed, this integrated physiological and psychological approach opens important therapeutic perspectives for ASD based on regulation of physiological rhythms (in particular, through the use of chronobiotics such as melatonin, and also through light exposure, use of regularly scheduled bedtime, wake up, meals, or activities) combined with synchronization of motor, emotional, and relational rhythms through developmental behavioral intervention such as the ESDM. Further studies are required to better ascertain the underlying mechanisms of physiologic alterations induced by desynchronization and to better understand the role of biological rhythms and rhythmicity in the development of social communication, repetitive behaviors, and interests or adaptation to changes, and therefore in the development of autism involving impairments in these domains.

REFERENCES


Frontiers in Pediatrics | Child and Neurodevelopmental Psychiatry
February 2015 | Volume 3 | Article 1 | 12


Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 20 August 2014; accepted: 05 January 2015; published online: 23 February 2015.


This article was submitted to Child and Neurodevelopmental Psychiatry, a section of the journal Frontiers in Pediatrics.

Copyright © 2015 Tordjman, Davlantis, Georgieff, Geoffray, Speranza, Anderson, Xavier, Botbol, Oriol, Bellissant, Vernay-Leconte, Fougerou, Hespel, Tavenard, Cohen, Kermarrec, Colinon, Bonmot and Dawson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.